o | Preliminary Proxy Statement | ||||
o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||||
x | Definitive Proxy Statement | ||||
o | Definitive Additional Materials | ||||
o | Soliciting Material Pursuant to §240.14a-12 |
x | No fee required. | ||||
o | Fee paid previously with preliminary materials. | ||||
o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
Page | |||||||||||
Report of the Audit Committee | |||||||||||
8:30 a.m., Eastern Time, on Thursday, Access to Live Webcast: www.virtualshareholdermeeting.com/ | ||
By mailing your Proxy Card | By telephone | By Internet | ||||||||||||||||||||
Cast your ballot, sign your proxy card and send by free post | Dial toll-free 24/7 1-800-690-6903 | Visit 24/7 www.proxyvote.com | ||||||||||||||||||||
Mark, sign and date your proxy card and return it in the postage-paid envelope included in your proxy materials. Your proxy card must arrive by May | Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m., Eastern Time, on May | Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m., Eastern Time, on May |
More Information | Board of Directors recommendation | Recommendation | |||||||||||||||
PROPOSAL 1: | Election of Three Class | Page 11 | FOR each nominee | ||||||||||||||
PROPOSAL 2: | Advisory Vote on Executive Compensation | Page 72 | FOR | ||||||||||||||
PROPOSAL 3: | Ratification of the Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, | Page 73 | FOR |
Corporate Governance Best Practices | ||||||||||||||||
Separate Board chair and chief executive officer | ü | |||||||||||||||
All directors are independent, other than our chief executive officer | ü | |||||||||||||||
100% independence among members of Audit, Compensation and Nominating and Corporate Governance Committees | ü | |||||||||||||||
Mandatory retirement age of 75 | ||||||||||||||||
ü | Diverse Board: ◦22% racially/ethnically diverse ◦Female Board chair ◦Female chair of Audit, Compensation and Nominating and Corporate Governance Committees | ü | ||||||||||||||
ü | ü | Robust executive and non-employee director Stock Ownership Guidelines | ||||||||||||||
ü | Annual self-evaluation of Board and committees, including assessment of individual directors | ü | Director commitments (overboarding) policy limiting the number of public-company boards on which our directors serve | |||||||||||||
ü | No shareholder rights plan (i.e., no “poison pill”) |
| | | | | | | Director Since | | | Independent | | | | | | Other Public Boards | | |||
| Name and Occupation | | | Age* | | | Yes | | | No | | | Committee Memberships* | | ||||||
| Bernadette Connaughton Former President Intercontinental of Bristol Myers Squibb Company | | | 64 | | | 2021 | | | X | | | | | | Organization, Leadership and Compensation (chair) Nominating and Corporate Governance | | | 3 | |
| Elliott Levy Venture Partner at 5AM Venture Management, LLC | | | 64 | | | April 2023 | | | X | | | | | | Audit Science and Technology | | | 2 | |
| Akshay Vaishnaw President of Alnylam Pharmaceuticals, Inc. | | | 60 | | | 2016 | | | X | | | | | | Organization, Leadership and Compensation Science and Technology | | | 1 | |
Director Since | Independent | Other Public Company Boards | ||||||||||||||||||||||||||||||||||||
Name and Occupation | Age* | Yes | No | Committee Memberships* | ||||||||||||||||||||||||||||||||||
Meeta Chatterjee Chief Strategy Officer of Sun Pharmaceutical Industries Ltd. | 69 | 2020 | X | Audit | 1 | |||||||||||||||||||||||||||||||||
Andrew Hirsch Chief Executive Officer of C4 Therapeutics, Inc. | 53 | 2017 | X | Audit Compensation | 1 | |||||||||||||||||||||||||||||||||
Gilmore O'Neill Chief Executive Officer of Editas Medicine, Inc. | 59 | 2022 | X | None | 1 |
Select Recent Business Highlights | ||||||||||||||||||||
Drive our lead product candidate, reni-cel (formerly known as EDIT-301) toward Biologics License Application and Commercialization | Strengthen and Focus Discovery to Build in vivo Editing Pipeline | Increase Business Development Activities and Monetize IP | ||||||||||||||||||
Achieved alignment with the Food and Drug Administration (“FDA”) that our RUBY clinical trial of reni-cel for severe sickle cell disease (“SCD”) is a single Phase 1/2/3 trial | ü | Hired new chief scientific officer with specific expertise aligned with Editas’ vision | ü | Created value through business development to complement core gene editing technology capabilities | ||||||||||||||||
ü | Exceeded our enrollment goal of 20 patients in the RUBY trial by year-end 2023 | ü | Leveraged robust intellectual property portfolio | |||||||||||||||||
ü | Granted Vertex Pharmaceuticals Incorporated (“Vertex”) a non-exclusive license for our Cas9 gene editing technology for certain uses, including in Vertex’s CASGEVYTM |
Compensation Highlights | |||||||||||||||||
Significant portion of named executive officers’ target compensation is performance-based ◦ Approximately ◦ Approximately | Annual performance-based cash bonus program for chief executive officer | |||||||||||||||||
25% of long-term incentive compensation for | Annual performance-based cash bonus program for other |
Director since 2021 Independent Director Committees: Compensation (Chair), Nominating and Corporate Governance |
Director since April 2023 Independent Director Committees: Audit, Science and Technology |
Director since 2016 Independent Director Committees: Compensation, Science and Technology |
Meeta Chatterjee, Ph.D. Age: Director since 2020 Independent Director Committees: Audit |
Andrew Hirsch Age: Director since 2017 Independent Director Committees: Audit, Compensation |
Gilmore O’Neill, M.B., M.M.Sc. Age: Director since June President and Chief Executive Officer of Editas Medicine |
Jessica Hopfield, Ph.D. Age: Director since 2018 Lead Independent Director Committees: Audit, Nominating and Corporate Governance (Chair), Science and Technology |
Emma Reeve Age: Director since 2021 Board Chair; Independent Director Committees: Audit (Chair), Nominating and Corporate Governance |
David Scadden, M.D. Age: Director since 2019 Independent Director Committees: Compensation, Science and Technology (Chair) |
Bernadette Connaughton Age: 65 Director since 2021 Independent Director Committees: Compensation (Chair), Nominating and Corporate Governance |
Elliott Levy, M.D. Age: 65 Director since April 2023 Independent Director Committees: Audit, Science and Technology |
Akshay Vaishnaw, M.D., Ph.D. Age: 61 Director since 2016 Independent Director Committees: Compensation, Science and Technology |
Age: Executive Vice President and Chief Joined Editas in |
Erick Lucera Age: 56 Executive Vice President and Chief Financial Officer Joined Editas in May 2023 |
Baisong Mei, M.D., Ph.D. Age: Senior Executive Vice President and Chief Medical Officer Joined Editas in 2022 |
16 | Executive Vice President and Chief Financial Officer Joined Editas in 2020 |
Topic | What We Heard | Our Response | ||||||||||||
In June 2023, we appointed Emma Reeve, an independent director, as our new Board chair. Ms. Reeve is an accomplished executive with more than 25 years of global financial and operational experience across pharmaceutical, medical device, and biopharmaceutical companies. We believe this experience, together with her in-depth understanding of our business strategies and day-to-day operations, makes her well suited to lead the Board as we continue to execute on our corporate strategy. We periodically review our Board to ensure its members have broad experience and skills in areas important to our operation. In April 2023, we strengthened our Board with the addition of Elliott Levy, M.D. Dr. Levy is an accomplished drug development executive with more than 20 years of global research and development expertise. We believe his significant experience and expertise will help us accelerate reni-cel toward commercialization and contribute to the development of our in vivo pipeline. |
Topic | Our Response | ||||||||||
Overboarding Policy | Stockholders | We believe that Accordingly, in developing the limits provided by | Based on this guidance, our Board determined that the | ||||||||
2023 Annual Meeting Results | Stockholders wanted to understand what may have impacted the results for one nominee to our Board in 2023. | In reviewing the results of | |||||||||
In connection with our annual governance review, these results were discussed with our Nominating and Corporate Governance We |
Experience, Competencies & Skills | Director | |||||||||||
Experience serving as a public company chief executive officer or in other senior leadership roles hones skills in core management areas - such as strategic planning, financial reporting, compliance, risk management and leadership development. | ||||||||||||
Directors with backgrounds in academia, science and technology, and, in particular, the research and development of genomic medicines, will better enable us to develop a robust pipeline of medicines for people living with serious diseases around the world. | ||||||||||||
Public company board experience provides insight into new and alternative practices which informs our commitment to excellence in corporate governance and helps ensure that the Board is functioning as an effective and cohesive oversight body with independent perspectives. | ||||||||||||
Strategy/Business Development | Experience in senior strategic and business development roles helps inform our strategy with respect to in-licensing complementary technologies, developing partnerships, and monetizing our intellectual property portfolio. | |||||||||||
Commitment to Company Values and Goals | Commitment to our company and its values and goals strengthens the contributions of directors to our company and its prospects for success. |
Editas Background and Select Business Highlights |
Ex Vivo Hemoglobinopathies | • ◦exceeded our enrollment goal of 20 patients in the RUBY trial by year-end 2023; ◦provided clinical data updates in June 2023 and December 2023 from both the RUBY trial and our Phase 1/2 EdiTHAL clinical | ||||||
In Vivo Medicines | • ◦hired a new Chief Scientific Officer, Linda C. Burkly, who brings three decades of experience in | ||||||||
• ◦entered into a license agreement with Vor Biopharma Inc. (“Vor Bio”), providing Vor Bio a non-exclusive license for the development of ◦ |
Compensation Highlights |
• |
Annual Performance-based Cash Bonus Program: Since 2021 our annual performance-based cash bonus program has provided for independent weighting of corporate and individual achievement to calculate the bonus payout for our employees, including our named executive officers other than our chief executive officer, (i) chief executive (ii) other named executive officers: 80% based on corporate performance, 20% based on individual performance. In February | ||||
• PSUs retained as part of (i) 25% in the form of performance-based restricted stock unit (“PSU”) awards that vest only upon achievement by February (ii) 25% in the form of time-based vesting restricted stock unit (“RSU”) awards; and (iii) 50% in the form of time-based vesting stock options. |
Element of Compensation | Features | |||||||||||||
Base Salary | Attract, retain and reward talented executives needed to drive our business. | Fixed component of compensation to provide financial stability, based on responsibilities, experience, internal equity, performance and peer company data. | ||||||||||||
Annual Performance-based Cash Bonuses | Motivate the achievement of business goals that the Compensation Committee and the Board believe are important to the overall success of the business and will enhance stockholder value over time. | Variable component of compensation tied to the achievement of pre-determined corporate performance goals, and for executive officers other than our chief executive officer, on the achievement of pre-determined individual goals that align with our overall strategic and operational priorities. | ||||||||||||
Annual Equity Incentives | Assist in retaining our named executive officers and aligning their interests with those of our stockholders by allowing them to participate in the longer-term success of our company as reflected in the appreciation of our stock price. | Variable component of compensation in the form of stock options and RSUs typically subject to multi-year vesting based on continued service, the value of which is tied to the performance of our common stock price, as well as PSUs earned upon achievement of pre-established performance goals within specified time periods. |
What We Do | What We Don’t Do | |||||||||||||
Maintain and evaluate annually an industry-specific peer group for benchmarking pay | No employment agreements that guarantee a certain compensation level or employment term | |||||||||||||
No guaranteed annual salary increases or guaranteed bonuses | ||||||||||||||
Balance short-and long-term incentives (through annual cash bonuses and equity awards) | No single-trigger vesting in connection with a change-in-control for equity awards | |||||||||||||
Maintain a compensation | No excessive executive perquisites or personal benefits | |||||||||||||
Set robust executive and non-employee director Stock Ownership Guidelines | No hedging or pledging or speculative transaction in our securities | |||||||||||||
Use multiple performance measures to determine incentive payouts, include caps on annual incentive payments | No re-pricing of equity awards without | |||||||||||||
Engage independent compensation consultant | No excise tax gross-ups |
Adicet Bio, Inc. | ||||||||||||||
Allogene Therapeutics, Inc. | Fate Therapeutics, Inc. | |||||||||||||
Arrowhead Pharmaceuticals, Inc. | Intellia Therapeutics, Inc. | |||||||||||||
Arvinas, Inc. | Iovance Biotherapeutics, Inc. | |||||||||||||
Beam Therapeutics Inc. | ||||||||||||||
Kodiak Sciences Inc. | ||||||||||||||
Mirati Therapeutics, Inc. | ||||||||||||||
CRISPR Therapeutics AG |
| Company | | | Market Capitalization (Dollar Amounts in Millions)(1) | | | Research and Development Expenses (Dollar Amounts in Millions)(2) | | | Number of Employees(3) | | |||||||||
| Median Company in 2022 Peer Group | | | | $ | 3,924 | | | | | $ | 176 | | | | | | 237 | | |
| Editas | | | | $ | 4,466 | | | | | $ | 171 | | | | | | 235 | | |
| Editas Percentile | | | | | 55th | | | | | | 45th | | | | | | 50th | | |
Company | Market Capitalization (Dollar Amounts in Millions)(1) | Research and Development Expenses (Dollar Amounts in Millions)(2) | Number of Employees(3) | ||||||||
Median Company in 2023 Peer Group | $ | 2,029 | $ | 253 | 329 | ||||||
Editas | $ | 1,019 | $ | 164 | 264 | ||||||
Editas Percentile | 30th | 25th | 30th |
Adicet Bio, Inc. | Replimune Group, Inc. | |||||||||||||
Allogene Therapeutics, Inc. | ||||||||||||||
AlloVir, Inc.* | Fate Therapeutics, Inc. | |||||||||||||
Intellia Therapeutics, Inc. | Sangamo Therapeutics, Inc. | |||||||||||||
Arvinas, Inc. | Iovance Biotherapeutics, Inc. | |||||||||||||
Beam Therapeutics Inc. | Verve Therapeutics, Inc. | |||||||||||||
REGENXBIO Inc. |
| Company | | | Market Capitalization (Dollar Amounts in Millions)(1) | | | Research and Development Expenses (Dollar Amounts in Millions)(2) | | | Number of Employees(3) | | |||||||||
| Median Company in 2023 Peer Group | | | | $ | 2,029 | | | | | $ | 253 | | | | | | 329 | | |
| Editas | | | | $ | 1,019 | | | | | $ | 164 | | | | | | 264 | | |
| Editas Percentile | | | | | 30th | | | | | | 25th | | | | | | 30th | | |
Company | Market Capitalization (Dollar Amounts in Millions)(1) | Research and Development Expenses (Dollar Amounts in Millions)(2) | Number of Employees(3) | ||||||||
Median Company in 2024 Peer Group | $ | 880 | $ | 292 | 341 | ||||||
Editas | $ | 688 | $ | 235 | 210 | ||||||
Editas Percentile | 35th | 40th | 25th |
| Name | | | 2021 Base Salary ($) | | | 2022 Base Salary ($) | | | Increase of 2022 over 2021 | | |||||||||
| Gilmore O’Neill | | | | | N/A | | | | | | 625,000 | | | | | | N/A | | |
| Michelle Robertson | | | | | 450,000 | | | | | | 450,000 | | | | | | — | | |
| Bruce Eaton | | | | | 430,000 | | | | | | 449,350 | | | | | | 5% | | |
| Baisong Mei | | | | | N/A | | | | | | 450,000 | | | | | | N/A | | |
| Mark S. Shearman | | | | | 470,000 | | | | | | 493,265 | | | | | | 5% | | |
| James Mullen | | | | | 625,000 | | | | | | 655,000 | | | | | | 5% | | |
Name | 2022 Base Salary ($) | 2023 Base Salary ($) | Increase in 2023 over 2022 | |||||||||||
Gilmore O’Neill | 625,000 | 641,400 | (1) | 2.6 | % | |||||||||
Erick Lucera | — | 470,000 | — | |||||||||||
Linda C. Burkly | — | 495,000 | — | |||||||||||
Baisong Mei | 450,000 | 460,125 | (1) | 2.3 | % | |||||||||
Michelle Robertson | 450,000 | 470,250 | 4.5 | % | ||||||||||
Bruce Eaton | 449,350 | 469,571 | 4.5 | % |
Component Calculation | |||||||||||||||||||||||||||||||||||||||||||||||||
Company Performance Component | 80% Weighting | Base Salary | Target Bonus Percentage | Corporate Goal Achievement Percentage | Company Performance Component | ||||||||||||||||||||||||||||||||||||||||||||
Individual Performance Component | 20% Weighting | Base Salary | Target Bonus Percentage | Individual Goal Achievement Percentage (0-130%) | Individual Performance Component | ||||||||||||||||||||||||||||||||||||||||||||
Total Annual Bonus Payout |
Name | ||||||||||||
Gilmore O’Neill | ||||||||||||
| Name | | | Relative Weighting | | | Actual Achievement for 2022 | | ||||||
| Advance in vivo medicines portfolio | | | | | 45% | | | | | | 25% | | |
Name | Relative Weighting (Base) | Relative Weighting (Stretch) | Actual Achievement for 2023 | ||||||||
Ex Vivo Hemoglobinopathies | 60% | 15% | 66% |
Build and Advance In Vivo Drug Discovery Pipeline | 20% | 10% | 11% |
Business Development | 10% | 20% | 13% |
Financial | 5% | —% | 5% |
Culture and Organization | 5% | —% | 7% |
Total | 100% | 45% | 102% |
| Name | | | Target Bonus Amount($) | | | Company Performance Component($) | | | Individual Performance Component($) | | | Total Annual Performance- based Cash Bonus Earned($) | | ||||||||||||
| Gilmore O’Neill | | | | | 218,836(1) | | | | | | 201,329 | | | | | | N/A(2) | | | | | | 201,329 | | |
| Michelle Robertson | | | | | 202,500 | | | | | | 149,040 | | | | | | 40,500 | | | | | | 189,540 | | |
| Bruce Eaton | | | | | 202,208 | | | | | | 148,825 | | | | | | 40,442 | | | | | | 189,266 | | |
| Baisong Mei | | | | | 90,000(1) | | | | | | 66,240 | | | | | | 18,000 | | | | | | 84,240 | | |
| Mark Shearman | | | | | 221,969 | | | | | | 163,369 | | | | | | 44,394 | | | | | | 207,763 | | |
| James Mullen | | | | | 393,000 | | | | | | 361,560 | | | | | | N/A(2) | | | | | | 361,560 | | |
Name | Target Bonus Amount($) | Company Performance Component($) | Individual Performance Component($) | Total Annual Performance- based Cash Bonus Earned($) | ||||||||||||||||
Gilmore O’Neill | 384,840 | 392,537 | N/A | (1) | 392,537 | |||||||||||||||
Erick Lucera | 141,000 | (2) | 115,056 | 31,020 | 146,076 | |||||||||||||||
Linda C. Burkly | 111,375 | (2) | 90,882 | 22,275 | 113,157 | |||||||||||||||
Baisong Mei | 184,050 | 150,185 | 36,810 | 186,995 | ||||||||||||||||
Michelle Robertson(3) | 211,613 | N/A | N/A | N/A | ||||||||||||||||
Bruce Eaton | 211,307 | 172,426 | 42,262 | 214,688 |
| Name | | | 2022 Stock Option Awards(1) | | | 2022 RSUs(2) | | | 2022 PSUs(3) | | |||||||||
| Michelle Robertson | | | | | 157,580 | | | | | | 53,499 | | | | | | 53,499 | | |
| Bruce Eaton | | | | | 110,732 | | | | | | 37,593 | | | | | | 37,593 | | |
| Mark Shearman(4) | | | | | 93,398 | | | | | | 31,709 | | | | | | 54,352 | | |
Name | 2023 Stock Option Awards(1) | 2023 RSUs(2) | 2023 PSUs(3) | ||||||||
Gilmore O’Neill(4) | 150,000 | 50,000 | 85,000 | ||||||||
Baisong Mei(4) | 54,000 | 18,000 | 36,000 | ||||||||
Michelle Robertson | 94,500 | 31,500 | 31,500 | ||||||||
Bruce Eaton | 50,000 | 16,700 | 16,700 |
| Name | | | 2022 Stock Option Awards | | | 2022 RSUs | | | 2022 PSUs | | |||||||||
| Gilmore O’Neill(1) | | | | | 950,209 | | | | | | 86,655 | | | | | | 216,637 | | |
| Baisong Mei(2) | | | | | 171,602 | | | | | | 58,372 | | | | | | 58,372 | | |
Name | 2023 Stock Option Awards | 2023 RSUs | 2023 PSUs | ||||||||
Erick Lucera(1) | 155,800 | 77,900 | 77,900 | ||||||||
Linda C. Burkly(2) | 135,500 | 45,167 | 45,167 |
Group | Ownership Level | ||||||||
Chief Executive Officer | 3x Base Salary | ||||||||
Other Executive Officers | 1x Base Salary | ||||||||
Non-Employee Directors | 3x Annual Cash Retainer |
Respectfully submitted, | ||||||
The Organization, Leadership and Compensation | ||||||
Committee of the Board | ||||||
Bernadette Connaughton, Chair | ||||||
Andrew Hirsch | ||||||
David Scadden, M.D. | ||||||
Akshay Vaishnaw, M.D., Ph.D. |
| Name and Principal Position | | | Year | | | Salary ($) | | | Bonus ($)(1) | | | Stock Awards ($)(2) | | | Option Awards ($)(3) | | | Non-Equity Incentive Plan Compensation ($)(4) | | | All Other Compensation ($)(5) | | | Total ($) | | ||||||||||||||||||||||||
| Gilmore O’Neill, M.B., M.M.Sc.(6) | | | | | 2022 | | | | | | 355,769 | | | | | | — | | | | | | 999,999 | | | | | | 7,495,059 | | | | | | 201,329 | | | | | | 6,744 | | | | | | 9,058,900 | | |
| President and Chief Executive Officer | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Michelle Robertson | | | | | 2022 | | | | | | 450,915 | | | | | | — | | | | | | 924,998 | | | | | | 1,849,343 | | | | | | 189,540 | | | | | | 7,290 | | | | | | 3,422,086 | | |
| Executive Vice President and Chief | | | | | 2021 | | | | | | 415,754 | | | | | | — | | | | | | 627,408 | | | | | | 977,865 | | | | | | 218,700 | | | | | | 7,290 | | | | | | 2,247,017 | | |
| Financial Officer | | | | | 2020 | | | | | | 387,692 | | | | | | 140,000 | | | | | | 613,000 | | | | | | 2,374,080 | | | | | | 112,880 | | | | | | 6,690 | | | | | | 3,634,342 | | |
| Bruce Eaton, Ph.D.(7) | | | | | 2022 | | | | | | 448,978 | | | | | | 140,000 | | | | | | 649,983 | | | | | | 1,299,540 | | | | | | 189,267 | | | | | | 7,980 | | | | | | 2,735,748 | | |
| Executive Vice President and Chief Business Officer | | | | | 2021 | | | | | | 386,624 | | | | | | — | | | | | | 717,568 | | | | | | 520,351 | | | | | | 208,980 | | | | | | 7,290 | | | | | | 1,840,813 | | |
| Baisong Mei, M.D., Ph.D.(8) | | | | | 2022 | | | | | | 199,038 | | | | | | 100,000 | | | | | | 874,996 | | | | | | 1,748,762 | | | | | | 84,240 | | | | | | 3,711 | | | | | | 3,010,747 | | |
| Senior Vice President and Chief Medical Officer | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| Mark Shearman, Ph.D.(9) | | | | | 2022 | | | | | | 492,818 | | | | | | — | | | | | | 548,249 | | | | | | 1,096,110 | | | | | | 207,763 | | | | | | 7,980 | | | | | | 2,352,919 | | |
| Former Executive Vice President and Chief Scientific Officer | | | | | 2021 | | | | | | 253,077 | | | | | | 247,500 | | | | | | 1,609,963 | | | | | | 1,299,984 | | | | | | 133,909 | | | | | | 5,405 | | | | | | 3,549,838 | | |
| James Mullen(10) | | | | | 2022 | | | | | | 654,423 | | | | | | — | | | | | | — | | | | | | — | | | | | | 361,560 | | | | | | 34,980 | | | | | | 1,050,963 | | |
| Executive Chair; Former President and Chief Executive Officer | | | | | 2021 | | | | | | 540,865 | | | | | | — | | | | | | — | | | | | | 5,780,000 | | | | | | 361,644 | | | | | | 32,002 | | | | | | 6,714,511 | | |
Name and Principal Position | Year | Salary ($) | Bonus ($)(1) | Stock Awards ($)(2) | Option Awards ($)(3) | Non-Equity Incentive Plan Compensation ($)(4) | All Other Compensation ($)(5) | Total ($) | ||||||||||||||||||
Gilmore O’Neill, M.B., M.M.Sc.(6) | 2023 | 641,092 | — | 436,000 | 915,390 | 392,537 | 7,290 | 2,392,309 | ||||||||||||||||||
President and Chief Executive Officer | 2022 | 355,769 | — | 999,999 | 7,495,059 | 201,329 | 6,744 | 9,058,900 | ||||||||||||||||||
Erick Lucera(7) | 2023 | 285,615 | — | 748,619 | 1,034,512 | 146,076 | 794 | 2,215,616 | ||||||||||||||||||
Executive Vice President and Chief Financial Officer | ||||||||||||||||||||||||||
Linda C. Burkly, Ph.D.(8) | 2023 | 209,423 | — | 391,146 | 815,710 | 113,157 | 7,612 | 1,537,048 | ||||||||||||||||||
Executive Vice President and Chief Scientific Officer | ||||||||||||||||||||||||||
Baisong Mei, M.D., Ph.D.(9) | 2023 | 459,930 | — | 156,960 | 329,540 | 186,995 | 7,980 | 1,141,405 | ||||||||||||||||||
Senior Vice President and Chief Medical Officer | 2022 | 199,038 | 100,000 | 874,996 | 1,748,762 | 84,240 | 3,711 | 3,010,747 | ||||||||||||||||||
Michelle Robertson(10) | 2023 | 303,464 | — | 274,680 | 823,799 | — | 175,553 | 1,577,496 | ||||||||||||||||||
Former Executive Vice President and Chief Financial Officer | 2022 | 450,915 | — | 924,998 | 1,849,343 | 189,540 | 7,290 | 3,422,086 | ||||||||||||||||||
2021 | 415,754 | — | 627,408 | 977,865 | 218,700 | 7,290 | 2,247,017 | |||||||||||||||||||
Bruce Eaton, Ph.D.(11) | 2023 | 469,182 | — | 145,624 | 396,914 | 214,688 | 78,980 | 1,305,388 | ||||||||||||||||||
Former Executive Vice President and Chief Business Officer | 2022 | 448,978 | 140,000 | 649,983 | 1,299,540 | 189,267 | 7,980 | 2,735,748 | ||||||||||||||||||
2021 | 386,624 | — | 717,568 | 520,351 | 208,980 | 7,290 | 1,840,813 |
Name | Grant Date Fair Value PSUs ($) | |||||||||||
Gilmore O’Neill | ||||||||||||
748,619 | ||||||||||||
Linda C. Burkly | 391,146 | |||||||||||
Baisong Mei | 313,920 | |||||||||||
Michelle Robertson | ||||||||||||
Bruce Eaton | ||||||||||||
Estimated Future Payouts Under Non-Equity Incentive Plan Awards(3) | Estimated Future Payouts Under Equity Incentive Plan Awards(4) | All Other Stock Awards: Number of Shares of Stock or Units (#) | All Other Option Awards: Number of Securities Underlying Options (#) | Exercise or Base Price of Option Awards ($) | Grant Date Fair Value of Stock and Option Awards(5) ($) | ||||||||||||||||||||||||||||||||||||||||||
Name(1) | Date of Grant | Grant Approval Date(2) | Threshold ($) | Target ($) | Maximum ($) | Threshold (#) | Target (#) | Maximum (#) | |||||||||||||||||||||||||||||||||||||||
Gilmore O’Neill | — | 384,840 | 558,018 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | — | — | 50,000 | (6) | — | — | 436,000 | |||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | — | — | — | 150,000 | (6) | 8.72 | 915,390 | |||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | 85,000 | — | — | — | — | 0 | ||||||||||||||||||||||||||||||||||||
Erick Lucera | — | 141,000 | 200,220 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||
5/17/2023 | 5/16/2023 | — | — | — | — | — | — | 77,900 | (6) | — | — | 748,619 | |||||||||||||||||||||||||||||||||||
5/17/2023 | 5/16/2023 | — | — | — | — | — | — | — | 155,800 | (7) | 9.61 | 1,034,512 | |||||||||||||||||||||||||||||||||||
5/17/2023 | 5/16/2023 | — | — | — | — | 77,900 | — | — | — | — | 0 | ||||||||||||||||||||||||||||||||||||
Linda C. Burkly | — | 111,375 | 158,153 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||
7/24/2023 | — | — | — | — | — | — | — | 45,167 | (6) | — | — | 391,146 | |||||||||||||||||||||||||||||||||||
7/24/2023 | — | — | — | — | — | — | — | — | 135,500 | (7) | 8.66 | 815,710 | |||||||||||||||||||||||||||||||||||
7/24/2023 | — | — | — | — | — | 45,167 | — | — | — | — | 0 | ||||||||||||||||||||||||||||||||||||
Baisong Mei | — | 184,050 | 261,351 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | — | — | 18,000 | (6) | — | — | 156,960 | |||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | — | — | — | 54,000 | (6) | 8.72 | 329,540 | |||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | 36,000 | — | — | — | — | 0 | ||||||||||||||||||||||||||||||||||||
Michelle Robertson | — | 211,613 | 300,490 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | — | — | 31,500 | (6) | — | — | 274,680 | |||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | — | — | — | 94,500 | (6) | 8.72 | 576,696 | |||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | 31,500 | — | — | — | — | 0 | ||||||||||||||||||||||||||||||||||||
5/16/2023 | — | — | — | — | — | — | — | — | — | — | 247,103 | (8) | |||||||||||||||||||||||||||||||||||
Bruce Eaton | — | 211,307 | 300,056 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | — | — | 16,700 | (6) | — | — | 145,624 | |||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | — | — | — | 50,000 | (6) | 8.72 | 305,130 | |||||||||||||||||||||||||||||||||||
3/2/2023 | 2/10/2023 | — | — | — | — | 16,700 | — | — | — | — | 0 | ||||||||||||||||||||||||||||||||||||
10/3/2023 | — | — | — | — | — | — | — | — | — | — | 91,784 | (8) |
| | | Date of Grant | | | Grant Approval Date(2) | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards(3) | | | Estimated Future Payouts Under Equity Incentive Plan Awards(4) | | | All Other Stock Awards: Number of Shares of Stock or Units (#) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | | Exercise or Base Price of Option Awards ($) | | | Grant Date Fair Value of Stock and Option Awards(5) | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name(1) | | | Threshold ($) | | | Target ($) | | | Maximum ($) | | | Threshold (#) | | | Target (#) | | | Maximum (#) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gilmore O’Neill | | | | | | | | | | | | | | | | | — | | | | | | 218,836 | | | | | | 328,253 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/2/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 86,655(6) | | | | | | — | | | | | | — | | | | | | 999,999 | | | ||
| | | 6/2/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 950,209(7) | | | | | | 11.54 | | | | | | 7,495,059 | | | ||
| | | 6/2/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 216,637 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0 | | | ||
Michelle Robertson | | | | | | | | | | | | | | | | | — | | | | | | 202,500 | | | | | | 295,650 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 53,499(7) | | | | | | — | | | | | | — | | | | | | 924,998 | | | ||
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 157,580(7) | | | | | | 17.29 | | | | | | 1,849,343 | | | ||
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 53,499 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0 | | | ||
Bruce Eaton | | | | | | | | | | | | | | | | | — | | | | | | 202,208 | | | | | | 295,223 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 37,593(7) | | | | | | — | | | | | | — | | | | | | 649,983 | | | ||
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 110,732(7) | | | | | | 17.29 | | | | | | 1,299,540 | | | ||
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 37,593 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0 | | | ||
Baisong Mei | | | | | | | | | | | | | | | | | — | | | | | | 90,000 | | | | | | 131,400 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 7/18/2022 | | | | | | 7/15/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 58,372(6) | | | | | | — | | | | | | — | | | | | | 874,996 | | | ||
| | | 7/18/2022 | | | | | | 7/15/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 171,602(7) | | | | | | 14.99 | | | | | | 1,748,762 | | | ||
| | | 7/18/2022 | | | | | | 7/15/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 58,372 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0 | | | ||
Mark Shearman | | | | | | | | | | | | | | | | | — | | | | | | 221,969 | | | | | | 324,075 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 31,709(7) | | | | | | — | | | | | | — | | | | | | 548,249 | | | ||
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | ��� | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 93,398(7) | | | | | | 17.29 | | | | | | 1,096,110 | | | ||
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 54,352 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 0 | | | ||
James Mullen | | | | | — | | | | | | — | | | | | | — | | | | | | 393,000 | | | | | | 589,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | | | | | Option Awards(1) | | | Stock Awards(2) | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Options Exercisable (#) | | | Number of Securities Underlying Unexercised Options Unexercisable (#) | | | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of shares or units of stock that have not vested (#) | | | Market value of shares or units of stock that have not vested (#) | | | Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#) | | | Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($) | | ||||||||||||||||||||||||||||||
Gilmore O’Neill | | | | | 6/2/2022 | | | | | | — | | | | | | 950,209(3) | | | | | | — | | | | | | 11.54 | | | | | | 6/1/2032 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/2/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 86,655(4) | | | | | | 768,630 | | | | | | — | | | | | | — | | | ||
| | | 6/2/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 216,637(5) | | | | | | 1,921,570 | | | ||
Michelle Robertson | | | | | 1/9/2020 | | | | | | 82,500 | | | | | | 32,500(6) | | | | | | — | | | | | | 30.65 | | | | | | 1/18/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 1/9/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,000(7) | | | | | | 88,700 | | | | | | — | | | | | | — | | | ||
| | | 3/2/2021 | | | | | | 14,086 | | | | | | 18,111(8) | | | | | | — | | | | | | 45.69 | | | | | | 3/1/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/2/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,796(9) | | | | | | 51,411 | | | | | | — | | | | | | — | | | ||
| | | 6/2/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 8,942(10) | | | | | | 79,316 | | | ||
| | | 2/10/2022 | | | | | | 32,829 | | | | | | 124,751(11) | | | | | | — | | | | | | 17.29 | | | | | | 2/9/2032 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 53,499(12) | | | | | | 474,536 | | | | | | — | | | | | | — | | | ||
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 53,499(5) | | | | | | 474,536 | | | ||
Bruce Eaton | | | | | 2/5/2018 | | | | | | 110,000 | | | | | | — | | | | | | — | | | | | | 33.98 | | | | | | 2/4/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/6/2019 | | | | | | 46,719 | | | | | | 2,031(13) | | | | | | — | | | | | | 21.10 | | | | | | 2/5/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/6/2019 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 508(14) | | | | | | 4,506 | | | | | | — | | | | | | — | | | ||
| | | 2/6/2020 | | | | | | 31,880 | | | | | | 13,127(15) | | | | | | — | | | | | | 28.05 | | | | | | 2/5/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/6/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,344(16) | | | | | | 20,791 | | | | | | — | | | | | | — | | | ||
| | | | | 3/2/2021 | | | | | | 7,496 | | | | | | 9,637(8) | | | | | | — | | | | | | 45.69 | | | | | | 3/1/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 3/2/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,084(17) | | | | | | 27,355 | | | | | | — | | | | | | — | | |
| | | | | 6/2/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 6,944(10) | | | | | | 61,593 | | |
| | | | | 2/10/2022 | | | | | | 23,069 | | | | | | 87,663(11) | | | | | | — | | | | | | 17.29 | | | | | | 2/9/2032 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 37,593(12) | | | | | | 333,450 | | | | | | — | | | | | | — | | |
| | | | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 37,593(5) | | | | | | 333,450 | | |
Baisong Mei | | | | | 7/18/2022 | | | | | | — | | | | | | 171,602(18) | | | | | | — | | | | | | 14.99 | | | | | | 7/17/2032 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 7/18/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 58,372(19) | | | | | | 517,760 | | | | | | — | | | | | | — | | | ||
| | | 7/18/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 58,372(5) | | | | | | 517,760 | | |
Option Awards(1) | Stock Awards(2) | ||||||||||||||||||||||||||||||||||||||||||||||
Name | Grant Date | Number of Securities Underlying Unexercised Options Exercisable (#) | Number of Securities Underlying Unexercised Options Unexercisable (#) | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | Option Exercise Price ($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested (#) | Market Value of Shares or Units of Stock That Have Not Vested ($) | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have Not Vested (#) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have not Vested ($) | |||||||||||||||||||||||||||||||||||||
Gilmore O’Neill | 6/2/2022 | 356,328 | 593,881 | (3) | — | 11.54 | 6/1/2032 | — | — | — | — | ||||||||||||||||||||||||||||||||||||
6/2/2022 | — | — | — | — | — | 64,991 | (4) | 658,359 | — | — | |||||||||||||||||||||||||||||||||||||
6/2/2022 | — | — | — | — | — | — | — | 216,637 | (5) | 2,194,533 | |||||||||||||||||||||||||||||||||||||
3/2/2023 | 28,125 | 121,875 | (6) | — | 8.72 | 3/1/2033 | — | — | — | ||||||||||||||||||||||||||||||||||||||
3/2/2023 | — | — | — | — | — | 50,000 | (7) | 506,500 | — | — | |||||||||||||||||||||||||||||||||||||
3/2/2023 | — | — | — | — | — | — | — | 85,000 | (8) | 861,050 | |||||||||||||||||||||||||||||||||||||
Erick Lucera | 5/17/2023 | — | 155,800 | (9) | — | 9.61 | 5/16/2033 | — | — | — | — | ||||||||||||||||||||||||||||||||||||
5/17/2023 | — | — | — | — | — | 77,900 | (10) | 789,127 | — | — | |||||||||||||||||||||||||||||||||||||
5/17/2023 | — | — | — | — | — | — | — | 77,900 | (11) | 789,127 | |||||||||||||||||||||||||||||||||||||
Linda C. Burkly | 7/24/2023 | — | 135,000 | (12) | — | 8.66 | 7/23/2033 | — | — | — | — | ||||||||||||||||||||||||||||||||||||
7/24/2023 | — | — | — | — | — | 45,167 | (13) | 457,542 | — | — | |||||||||||||||||||||||||||||||||||||
7/24/2023 | — | — | — | — | — | — | — | 45,167 | (11) | 457,542 | |||||||||||||||||||||||||||||||||||||
Baisong Mei | 7/18/2022 | 60,775 | 110,827 | (14) | — | 14.99 | 7/17/2032 | — | — | — | — | ||||||||||||||||||||||||||||||||||||
7/18/2022 | — | — | — | — | — | 43,779 | (15) | 443,481 | — | — | |||||||||||||||||||||||||||||||||||||
7/18/2022 | — | — | — | — | — | — | — | 58,372 | (5) | 591,308 | |||||||||||||||||||||||||||||||||||||
3/2/2023 | 10,125 | 43,875 | (6) | — | 8.72 | 3/1/2033 | — | — | — | ||||||||||||||||||||||||||||||||||||||
3/2/2023 | — | — | — | — | — | 18,000 | (7) | 182,340 | — | — | |||||||||||||||||||||||||||||||||||||
3/2/2023 | — | — | — | — | — | — | — | 36,000 | (8) | 364,680 | |||||||||||||||||||||||||||||||||||||
Michelle Robertson(16) | 1/9/2020 | 102,500 | — | — | 30.65 | 1/18/2030 | — | — | — | — | |||||||||||||||||||||||||||||||||||||
3/2/2021 | 19,452 | — | — | 45.69 | 3/1/2031 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
2/10/2022 | 32,829 | — | — | 17.29 | 2/9/2032 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
3/2/2023 | 9,844 | — | — | 8.72 | 3/1/2033 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
Bruce Eaton(17) | 2/5/2018 | 110,000 | — | — | 33.98 | 2/4/2028 | — | — | — | — | |||||||||||||||||||||||||||||||||||||
2/6/2019 | 48,750 | — | — | 21.10 | 2/5/2029 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
2/6/2020 | 43,132 | 1,875 | (18) | — | 28.05 | 2/5/2030 | — | — | — | — | |||||||||||||||||||||||||||||||||||||
2/6/2020 | — | — | — | — | — | 469 | (19) | 4,751 | — | — | |||||||||||||||||||||||||||||||||||||
3/2/2021 | 11,779 | 5,354 | (20) | — | 45.69 | 3/1/2031 | — | — | — | — | |||||||||||||||||||||||||||||||||||||
3/2/2021 | — | — | — | — | — | 1,713 | (21) | 17,353 | — | — | |||||||||||||||||||||||||||||||||||||
6/2/2021 | — | — | — | — | — | — | — | 6,944 | (22) | 70,343 | |||||||||||||||||||||||||||||||||||||
2/10/2022 | 50,752 | 59,980 | (23) | — | 17.29 | 2/9/2032 | — | — | — | — | |||||||||||||||||||||||||||||||||||||
2/10/2022 | — | — | — | — | — | 21,146 | (24) | 214,209 | — | — | |||||||||||||||||||||||||||||||||||||
2/10/2022 | — | — | — | — | — | — | — | 37,593 | (5) | 380,817 | |||||||||||||||||||||||||||||||||||||
3/2/2023 | 9,375 | 40,625 | (6) | — | 8.72 | 3/1/2033 | |||||||||||||||||||||||||||||||||||||||||
3/2/2023 | — | — | — | — | — | 16,700 | (7) | 169,171 | — | — | |||||||||||||||||||||||||||||||||||||
3/2/2023 | — | — | — | — | — | — | — | 16,700 | (8) | 169,171 |
| | | | | | | | | Option Awards(1) | | | Stock Awards(2) | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Options Exercisable (#) | | | Number of Securities Underlying Unexercised Options Unexercisable (#) | | | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of shares or units of stock that have not vested (#) | | | Market value of shares or units of stock that have not vested (#) | | | Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#) | | | Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($) | | ||||||||||||||||||||||||||||||
Mark Shearman(20) | | | | | 6/14/2021 | | | | | | 19,769 | | | | | | 32,949(21) | | | | | | — | | | | | | 38.53 | | | | | | 6/13/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/14/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 24,525(22) | | | | | | 217,537 | | | | | | — | | | | | | — | | | ||
| | | 6/14/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 18,167(10) | | | | | | 161,141 | | | ||
| | | 2/10/2022 | | | | | | 19,458 | | | | | | 73,940(11) | | | | | | — | | | | | | 17.29 | | | | | | 2/9/2032 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 31,709(12) | | | | | | 281,259 | | | | | | — | | | | | | — | | | ||
| | | 2/10/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 54,352(5) | | | | | | 482,102 | | | ||
James Mullen | | | | | 3/27/2018 | | | | | | 23,076 | | | | | | — | | | | | | — | | | | | | 33.18 | | | | | | 3/26/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/12/2019 | | | | | | 11,538 | | | | | | — | | | | | | — | | | | | | 21.74 | | | | | | 6/11/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 6/10/2020 | | | | | | 11,538 | | | | | | — | | | | | | — | | | | | | 27.49 | | | | | | 6/9/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/2/2021 | | | | | | 341,978(23) | | | | | | — | | | | | | — | | | | | | 45.69 | | | | | | 3/1/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/2/2021 | | | | | | — | | | | | | — | | | | | | 196,637(24) | | | | | | 45.69 | | | | | | 3/1/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | Stock Awards | | |||||||||
| Name | | | Number of shares acquired on vesting (#) | | | Value realized on vesting ($)(1) | | ||||||
| Gilmore O’Neill | | | | | — | | | | | | — | | |
| Michelle Robertson | | | | | 13,978 | | | | | | 247,840 | | |
| Bruce Eaton | | | | | 14,065 | | | | �� | | 219,344 | | |
| Baisong Mei | | | | | — | | | | | | — | | |
| Mark Shearman | | | | | 17,260 | | | | | | 172,600 | | |
| James Mullen | | | | | — | | | | | | — | | |
Stock Awards | ||||||||
Name | Number of shares acquired on vesting (#) | Value realized on vesting ($)(1) | ||||||
Gilmore O’Neill | 21,664 | 209,491 | ||||||
Erick Lucera | — | — | ||||||
Linda C. Burkly | — | — | ||||||
Baisong Mei | 14,593 | 127,251 | ||||||
Michelle Robertson | 26,350 | 245,839 | ||||||
Bruce Eaton | 20,201 | 189,903 |
| | | | | | | Triggering Event | | |||||||||
| Name | | | Benefit | | | Resignation For Good Reason or Termination Without Cause ($) | | | Resignation For Good Reason or Termination Without Cause Upon or Within One Year Following a Change-in-Control ($) | | ||||||
| Gilmore O’Neill | | | Severance Payments(1) | | | | | 625,000 | | | | | | 625,000 | | |
| Bonus Payment(2) | | | | | 201,329 | | | | | | 201,329 | | | |||
| Continuation of Benefits | | | | | 7,676 | | | | | | 7,676 | | | |||
| Market Value of Stock Vesting(3) | | | | | — | | | | | | 2,690,200 | | | |||
| Total | | | | | 834,004 | | | | | | 3,524,205 | | | |||
| | | | | | | | | | | | | | | | | |
| Michelle Robertson | | | Severance Payments(1) | | | | | 450,000 | | | | | | 450,000 | | |
| Bonus Payment | | | | | —(4) | | | | | | 189,540(5) | | | |||
| Continuation of Benefits | | | | | 7,676 | | | | | | 7,676 | | | |||
| Market Value of Stock Vesting(3) | | | | | — | | | | | | 1,168,498 | | | |||
| Total | | | | | 457,676 | | | | | | 1,815,714 | | | |||
| | | | | | | | | | | | | |||||
| Bruce Eaton | | | Severance Payments(1) | | | | | 449,350 | | | | | | 449,350 | | |
| Bonus Payment | | | | | —(4) | | | | | | 189,267(5) | | | |||
| Continuation of Benefits | | | | | 7,676 | | | | | | 7,676 | | | |||
| Market Value of Stock Vesting(3) | | | | | — | | | | | | 781,145 | | | |||
| Total | | | | | 457,026 | | | | | | 1,427,438 | | | |||
| | | | | | | | | | | | | | | | | |
| Baisong Mei | | | Severance Payments(1) | | | | | 450,000 | | | | | | 450,000 | | |
| Bonus Payment | | | | | —(4) | | | | | | 84,240(5) | | | |||
| Continuation of Benefits | | | | | 7,676 | | | | | | 7,676 | | | |||
| Market Value of Stock Vesting(3) | | | | | — | | | | | | 1,035,519 | | | |||
| Total | | | | | 457,676 | | | | | | 1,577,435 | | | |||
| | | | | | | | | | | | | |||||
| Mark Shearman(6) | | | Severance Payments(1) | | | | | 493,265 | | | | | | 493,265 | | |
| Bonus Payment | | | | | —(4) | | | | | | 207,763(5) | | | |||
| Continuation of Benefits | | | | | 7,676 | | | | | | 7,676 | | | |||
| Market Value of Stock Vesting(3) | | | | | — | | | | | | 1,142,039 | | | |||
| Total | | | | | 500,941 | | | | | | 1,850,743 | | | |||
| | | | | | | | | | | | | | | | | |
| James Mullen | | | Severance Payments(1) | | | | | 655,000 | | | | | | 655,000 | | |
| Bonus Payment | | | | | —(4) | | | | | | 361,560(5) | | | |||
| Continuation of Benefits | | | | | 7,676 | | | | | | 7,676 | | | |||
| Market Value of Stock Vesting(3) | | | | | — | | | | | | — | | | |||
| Total | | | | | 662,676 | | | | | | 1,024,236 | | |
Triggering Event | ||||||||||||||||||||
Name | Benefit | Resignation For Good Reason or Termination Without Cause - No Change-in-Control ($) | Resignation For Good Reason or Termination Without Cause Within Three Months Prior To or One Year Following a Change-in-Control ($) | |||||||||||||||||
Gilmore O’Neill | Severance Payments(1) | 641,400 | 962,100 | |||||||||||||||||
Bonus Payment(2) | 392,537 | 392,537 | ||||||||||||||||||
Continuation of Benefits | 8,320 | 12,481 | ||||||||||||||||||
Market Value of Stock Vesting(3) | — | 4,392,285 | ||||||||||||||||||
Total | 1,042,257 | 5,759,403 | ||||||||||||||||||
Erick Lucera | Severance Payments(1) | 470,000 | 470,000 | |||||||||||||||||
Bonus Payment | — | (4) | 146,076 | (5) | ||||||||||||||||
Continuation of Benefits | 8,320 | 8,320 | ||||||||||||||||||
Market Value of Stock Vesting(3) | — | 1,659,270 | ||||||||||||||||||
Total | 478,320 | 2,283,666 | ||||||||||||||||||
Linda C. Burkly | Severance Payments(1) | 495,000 | 495,000 | |||||||||||||||||
Bonus Payment | — | (4) | 113,157 | (5) | ||||||||||||||||
Continuation of Benefits | 8,320 | 8,320 | ||||||||||||||||||
Market Value of Stock Vesting(3) | — | 1,114,268 | ||||||||||||||||||
Total | 503,320 | 1,730,746 | ||||||||||||||||||
Baisong Mei | Severance Payments(1) | 460,125 | 460,125 | |||||||||||||||||
Bonus Payment | — | (4) | 186,995 | (5) | ||||||||||||||||
Continuation of Benefits | 8,320 | 8,320 | ||||||||||||||||||
Market Value of Stock Vesting(3) | — | 1,643,673 | ||||||||||||||||||
Total | 468,445 | 2,299,114 | ||||||||||||||||||
Michelle Robertson(6) | Severance Payments | 470,250 | — | |||||||||||||||||
Bonus Payment | — | — | ||||||||||||||||||
Continuation of Benefits | 2,314 | — | ||||||||||||||||||
Market Value of Stock Vesting | — | — | ||||||||||||||||||
Total | 472,564 | — | ||||||||||||||||||
Bruce Eaton(7) | Severance Payments(1) | 469,571 | 469,571 | |||||||||||||||||
Bonus Payment | — | (4) | 214,688 | (5) | ||||||||||||||||
Continuation of Benefits | 23,714 | 23,714 | ||||||||||||||||||
Market Value of Stock Vesting(3) | — | 1,083,096 | ||||||||||||||||||
Total | 493,285 | 1,791,068 |
Year | Summary Compensation Table Total for Gilmore O’Neill ($)(1) | Summary Compensation Table Total for James Mullen ($)(1) | Summary Compensation Table Total for Cynthia Collins ($)(1) | Compensation Actually Paid to Gilmore O’Neill ($)(1)(2) | Compensation Actually Paid to James Mullen ($)(1)(2) | Compensation Actually Paid to Cynthia Collins ($)(1)(2) | Average Summary Compensation Table Total for Non-PEO NEOs ($)(3) | Average Compensation Actually Paid to Non-PEO NEOs ($)(3)(4) | Value of Initial Fixed $100 Investment Based On: | Net Loss ($)(in thousands) | |||||||||||||||||||||||||
Editas Total Shareholder Return ($) | Peer Group Total Shareholder Return ($)(5) | ||||||||||||||||||||||||||||||||||
2023 | 2,392,309 | — | — | 3,764,809 | — | — | 1,555,391 | 1,575,614 | 34.21 | 118.87 | (153,219) | ||||||||||||||||||||||||
2022 | 9,058,900 | 1,050,963 | — | 6,493,262 | (2,912,999) | — | 2,880,375 | 888,434 | 29.96 | 113.65 | (220,432) | ||||||||||||||||||||||||
2021 | — | 6,714,511 | 662,427 | — | 8,874,156 | (16,539,214) | 2,115,079 | (1,272,199) | 89.67 | 126.45 | (192,502) | ||||||||||||||||||||||||
2020 | — | — | 3,115,950 | — | — | 28,342,079 | 1,851,910 | 3,862,256 | 236.78 | 126.42 | (115,976) |
| Year | | | Summary Compensation Table Total for Gilmore O’Neill ($)(1) | | | Summary Compensation Table Total for James Mullen ($)(1) | | | Summary Compensation Table Total for Cynthia Collins ($)(1) | | | Compensation Actually Paid to Gilmore O’Neill ($)(1)(2) | | | Compensation Actually Paid to James Mullen ($)(1)(2) | | | Compensation Actually Paid to Cynthia Collins ($)(1)(2) | | | Average Summary Compensation Table Total for Non-PEO NEOs ($)(3) | | | Average Compensation Actually Paid to Non-PEO NEOs ($)(3)(4) | | | Value of Initial Fixed $100 Investment Based On: | | | Net Loss ($000s) | | ||||||||||||||||||||||||||||||||||||
| Editas Total Shareholder Return ($) | | | Peer Group Total Shareholder Return ($)(5) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2022 | | | | | 9,058,900 | | | | | | 1,050,963 | | | | | | — | | | | | | 6,493,262 | | | | | | (2,912,999) | | | | | | — | | | | | | 2,880,375 | | | | | | 888,433 | | | | | | 29.96 | | | | | | 111.27 | | | | | | (220,432) | | |
| 2021 | | | | | — | | | | | | 6,714,511 | | | | | | 662,427 | | | | | | — | | | | | | 8,874,155 | | | | | | (16,539,214) | | | | | | 2,115,079 | | | | | | (1,272,198) | | | | | | 89.67 | | | | | | 124.89 | | | | | | (192,502) | | |
| 2020 | | | | | — | | | | | | — | | | | | | 3,115,950 | | | | | | — | | | | | | — | ��� | | | | | 28,342,079 | | | | | | 1,851,910 | | | | | | 3,862,256 | | | | | | 236.78 | | | | | | 125.69 | | | | | | (115,976) | | |
| PEO Summary Compensation Total to CAP Reconciliation | | |||||||||||||||||||||||||||
| Year | | | PEO | | | Reported Summary Compensation Table Total for PEO($) | | | Minus: Reported Summary Compensation Table Value of Equity Awards($)(i) | | | Plus: Equity Award Adjustments($)(ii) | | | Compensation Actually Paid to PEO($) | | ||||||||||||
| 2022 | | | Gilmore O’Neill | | | | | 9,058,900 | | | | | | 8,495,057 | | | | | | 5,929,419 | | | | | | 6,493,262 | | |
| 2022 | | | James Mullen | | | | | 1,050,963 | | | | | | — | | | | | | (3,963,962) | | | | | | (2,912,999) | | |
| 2021 | | | James Mullen | | | | | 6,714,511 | | | | | | 5,780,000 | | | | | | 7,939,644 | | | | | | 8,874,155 | | |
| 2021 | | | Cynthia Collins | | | | | 662,427 | | | | | | — | | | | | | (17,201,641) | | | | | | (16,539,214) | | |
| 2020 | | | Cynthia Collins | | | | | 3,115,950 | | | | | | 2,123,015 | | | | | | 27,349,144 | | | | | | 28,342,079 | | |
Year | PEO | Reported Summary Compensation Table Total for PEO($) | Minus: Reported Summary Compensation Table Value of Equity Awards($)(i) | Plus: Equity Award Adjustments($)(ii) | Compensation Actually Paid to PEO($) | ||||||||||||
2023 | Gilmore O’Neill | 2,392,309 | 1,351,390 | 2,723,890 | 3,764,809 | ||||||||||||
2022 | Gilmore O’Neill | 9,058,900 | 8,495,057 | 5,929,419 | 6,493,262 | ||||||||||||
2022 | James Mullen | 1,050,963 | — | (3,963,962) | (2,912,999) | ||||||||||||
2021 | James Mullen | 6,714,511 | 5,780,000 | 7,939,645 | 8,874,156 | ||||||||||||
2021 | Cynthia Collins | 662,427 | — | (17,201,641) | (16,539,214) | ||||||||||||
2020 | Cynthia Collins | 3,115,950 | 2,123,015 | 27,349,144 | 28,342,079 |
| | | | | | | Equity Award Adjustments | | | | | | | | |||||||||||||||||||||||||||
| Year | | | PEO | | | Plus: Year-End Fair Value of Awards Granted During Applicable Year That Remain Unvested as of Year-End($) | | | Plus (Minus): Change in Fair Value as of Year- End of any Prior-Year Awards that Remain Unvested as of Year- End($) | | | Plus: Fair Value as of the Vesting Date of Awards Granted and Vested During the Applicable Year($) | | | Plus (Minus): Change in Fair Value as of the Vesting Date of any Prior-Year Awards that Vested During Applicable Year($) | | | Minus: Fair Value at Prior-Year-End of any Prior- Year Awards that Failed to Meet Applicable Vesting Conditions During the Applicable Year($) | | | Total Equity Awards Adjustments($) | | ||||||||||||||||||
| 2022 | | | Gilmore O’Neill | | | | | 5,929,419 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,929,419 | | |
| 2022 | | | James Mullen | | | | | — | | | | | | (1,881,816) | | | | | | — | | | | | | (1,113,655) | | | | | | 968,491 | | | | | | (3,963,962) | | |
| 2021 | | | James Mullen | | | | | 2,050,924 | | | | | | — | | | | | | 6,435,548 | | | | | | (546,827) | | | | | | — | | | | | | 7,939,644 | | |
| 2021 | | | Cynthia Collins | | | | | — | | | | | | — | | | | | | — | | | | | | (3,790,547) | | | | | | 13,411,094 | | | | | | (17,201,641) | | |
| 2020 | | | Cynthia Collins | | | | | 5,124,086 | | | | | | 17,997,080 | | | | | | 359,720 | | | | | | 3,868,258 | | | | | | — | | | | | | 27,349,144 | | |
Equity Award Adjustments | |||||||||||||||||||||||
Year | PEO | Plus: Year-End Fair Value of Awards Granted During Applicable Year That Remain Outstanding and Unvested as of Year-End($) | Plus (Minus): Change in Fair Value as of Year- End of any Prior-Year Awards that Remain Outstanding and Unvested as of Year- End($) | Plus: Fair Value as of the Vesting Date of Awards Granted and Vested During the Applicable Year($) | Plus (Minus): Change in Fair Value as of the Vesting Date of any Prior-Year Awards that Vested During Applicable Year($) | Minus: Fair Value at Prior-Year-End of any Prior- Year Awards that Failed to Meet Applicable Vesting Conditions During the Applicable Year($) | Total Equity Awards Adjustments($) | ||||||||||||||||
2023 | Gilmore O’Neill | 1,355,969 | 1,115,369 | 158,944 | 93,608 | — | 2,723,890 | ||||||||||||||||
2022 | Gilmore O’Neill | 5,929,419 | — | — | — | — | 5,929,419 | ||||||||||||||||
2022 | James Mullen | — | (1,881,816) | — | (1,113,655) | 968,491 | (3,963,962) | ||||||||||||||||
2021 | James Mullen | 2,050,924 | — | 6,435,548 | (546,827) | — | 7,939,645 | ||||||||||||||||
2021 | Cynthia Collins | — | — | — | (3,790,547) | 13,411,094 | (17,201,641) | ||||||||||||||||
2020 | Cynthia Collins | 5,124,086 | 17,997,080 | 359,720 | 3,868,258 | — | 27,349,144 |
| Average Non-PEO NEO Summary Compensation Total to CAP Reconciliation | | ||||||||||||||||||||||||
| Year | | | Average Reported Summary Compensation Table Total for Non-PEO NEOs($) | | | Minus: Average Reported Summary Compensation Table Value of Equity Awards for Non-PEO NEOs($) | | | Plus: Average Equity Award Adjustments($)(i) | | | Average Compensation Actually Paid to Non-PEO NEOs($) | | ||||||||||||
| 2022 | | | | | 2,880,375 | | | | | | 2,247,995 | | | | | | 256,053 | | | | | | 888,433 | | |
| 2021 | | | | | 2,115,079 | | | | | | 1,475,451 | | | | | | (1,911,826) | | | | | | (1,272,198) | | |
| 2020 | | | | | 1,851,910 | | | | | | 1,503,102 | | | | | | 3,513,447 | | | | | | 3,862,256 | | |
Year | Average Reported Summary Compensation Table Total for Non-PEO NEOs($) | Minus: Average Reported Summary Compensation Table Value of Equity Awards for Non-PEO NEOs($) | Plus: Average Equity Award Adjustments($)(i) | Average Compensation Actually Paid to Non-PEO NEOs($) | ||||||||||
2023 | 1,555,391 | 1,023,385 | 1,043,608 | 1,575,614 | ||||||||||
2022 | 2,880,375 | 2,247,995 | 256,054 | 888,434 | ||||||||||
2021 | 2,115,079 | 1,475,451 | (1,911,827) | (1,272,199) | ||||||||||
2020 | 1,851,910 | 1,503,102 | 3,513,448 | 3,862,256 |
| | | | Equity Award Adjustments | | | ||||||||||||||||||||||||||||||||
| Year | | | Plus: Average Year-End Fair Value of Awards Granted During Applicable Year That Remain Unvested as of Year-End($) | | | Plus (Minus): Average Change in Fair Value as of Year-End of any Prior-Year Awards that Remain Unvested as of Year-End($) | | | Plus: Average Fair Value as of the Vesting Date of Awards Granted and Vested During the Applicable Year($) | | | Plus (Minus): Average Change in Fair Value as of the Vesting Date of any Prior-Year Awards that Vested During Applicable Year($) | | | Minus: Average Fair Value at Prior-Year-End of any Prior-Year Awards that Failed to Meet Applicable Vesting Conditions During the Applicable Year($) | | | Total Average Equity Awards Adjustments($) | | ||||||||||||||||||
| 2022 | | | | | 950,131 | | | | | | (531,038) | | | | | | 164,771 | | | | | | (327,810) | | | | | | — | | | | | | 256,053 | | |
| 2021 | | | | | 827,448 | | | | | | (2,248,592) | | | | | | 64,051 | | | | | | (554,734) | | | | | | — | | | | | | (1,911,826) | | |
| 2020 | | | | | 3,900,667 | | | | | | 373,750 | | | | | | 53,290 | | | | | | (35,567) | | | | | | 778,692 | | | | | | 3,513,447 | | |
Equity Award Adjustments | ||||||||||||||||||||
Year | Plus: Average Year-End Fair Value of Awards Granted During Applicable Year That Remain Outstanding and Unvested as of Year-End($) | Plus (Minus): Average Change in Fair Value as of Year-End of any Prior-Year Awards that Remain Outstanding and Unvested as of Year-End($) | Plus: Average Fair Value as of the Vesting Date of Awards Granted and Vested During the Applicable Year($) | Plus (Minus): Average Change in Fair Value as of the Vesting Date of any Prior-Year Awards that Vested During Applicable Year($) | Minus: Average Fair Value at Prior-Year-End of any Prior-Year Awards that Failed to Meet Applicable Vesting Conditions During the Applicable Year($) | Total Average Equity Awards Adjustments($) | ||||||||||||||
2023 | 926,961 | 99,157 | 30,033 | (12,543) | — | 1,043,608 | ||||||||||||||
2022 | 950,131 | (531,038) | 164,771 | (327,810) | — | 256,054 | ||||||||||||||
2021 | 827,448 | (2,248,592) | 64,051 | (554,734) | — | (1,911,827) | ||||||||||||||
2020 | 3,900,667 | 373,750 | 53,290 | (35,567) | 778,692 | 3,513,448 |
| | | | Member Annual Fee | | | Chair Annual Fee | | ||||||
| Board of Directors | | | | $ | 40,000 | | | | | $ | 75,000 | | |
| Audit Committee | | | | $ | 7,500 | | | | | $ | 15,000 | | |
| Organization, Leadership and Compensation Committee | | | | $ | 5,000 | | | | | $ | 12,000 | | |
| Nominating and Corporate Governance Committee | | | | $ | 5,000 | | | | | $ | 10,000 | | |
| Science and Technology Committee | | | | $ | 5,000 | | | | | $ | 10,000 | | |
Member Annual Fee | Chair Annual Fee | |||||||
Board of Directors | $ | 40,000 | $ | 75,000 | ||||
Audit Committee | $ | 7,500 | $ | 15,000 | ||||
Organization, Leadership and Compensation Committee | $ | 5,000 | $ | 12,000 | ||||
Nominating and Corporate Governance Committee | $ | 5,000 | $ | 10,000 | ||||
Science and Technology Committee | $ | 5,000 | $ | 10,000 |
| Name | | | Fees earned or paid in cash ($) | | | Option awards ($)(1) | | | Total ($) | | |||||||||
| Meeta Chatterjee, Ph.D. | | | | | 57,500 | | | | | | 199,973 | | | | | | 257,473 | | |
| Bernadette Connaughton | | | | | 57,136 | | | | | | 199,973 | | | | | | 257,109 | | |
| Andrew Hirsch | | | | | 52,500 | | | | | | 199,973 | | | | | | 252,473 | | |
| Jessica Hopfield, Ph.D. | | | | | 92,500 | | | | | | 199,973 | | | | | | 292,473 | | |
| Emma Reeve | | | | | 60,000 | | | | | | 199,973 | | | | | | 259,973 | | |
| David T. Scadden, M.D. | | | | | 55,000 | | | | | | 199,973 | | | | | | 254,973 | | |
| Akshay K. Vaishnaw, M.D., Ph.D. | | | | | 50,000 | | | | | | 199,973 | | | | | | 249,973 | | |
Name | Fees earned or paid in cash ($) | Option awards ($)(1) | All Other Compensation | Total ($) | ||||||||||
Meeta Chatterjee, Ph.D. | 47,500 | 158,060 | — | 205,560 | ||||||||||
Bernadette Connaughton | 57,000 | 158,060 | — | 215,060 | ||||||||||
Andrew Hirsch | 52,500 | 158,060 | — | 210,560 | ||||||||||
Jessica Hopfield, Ph.D. | 73,008 | 158,060 | — | 231,068 | ||||||||||
Elliott Levy, M.D.(2) | 37,788 | 227,095 | — | 264,883 | ||||||||||
James C. Mullen(3) | — | — | 168,152 | 168,152 | ||||||||||
Emma Reeve | 80,179 | 158,060 | — | 238,239 | ||||||||||
David T. Scadden, M.D. | 55,000 | 158,060 | — | 213,060 | ||||||||||
Akshay K. Vaishnaw, M.D., Ph.D. | 50,000 | 158,060 | — | 208,060 |
| Plan category | | | Number of securities to be issued upon exercise of outstanding options, restricted stock units and rights | | | Weighted-average exercise price of outstanding options, warrants and rights(1) | | | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column(a)) | | |||||||||
| | | | (a) | | | (b) | | | (c) | | |||||||||
| Equity compensation plans approved by security holders(2) | | | | | 5,396,354 | | | | | $ | 26.83 | | | | | | 11,113,393 | | |
| Equity compensation plans not approved by security holders(3) | | | | | 1,378,864 | | | | | $ | 15.59 | | | | | | — | | |
| Total | | | | | 6,775,218 | | | | | $ | 24.54 | | | | | | 11,113,393 | | |
Plan category | Number of securities to be issued upon exercise of outstanding options, restricted stock units and rights | Weighted-average exercise price of outstanding options, warrants and rights(1) | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column(a)) | ||||||||
(a) | (b) | (c) | |||||||||
Equity compensation plans approved by security holders(2) | 6,566,557 | $18.06 | 12,285,740 | ||||||||
Equity compensation plans not approved by security holders(3) | 1,690,235 | $13.09 | — | ||||||||
Total | 8,256,792 | $17.04 | 12,285,740 |
| Name of Beneficial Owner | | | Shares Beneficially Owned | | | Percentage of Shares Beneficially Owned | | ||||||
| 5% Stockholders | | | | | | | | | | | | | |
| State Street Corporation(1) | | | | | 9,222,236 | | | | | | 13.4% | | |
| BlackRock Inc.(2) | | | | | 7,338,742 | | | | | | 10.6% | | |
| The Vanguard Group, Inc.(3) | | | | | 6,873,123 | | | | | | 10.0% | | |
| Named Executive Officers and Directors | | | | | | | | | | | | | |
| Meeta Chatterjee, Ph.D.(4) | | | | | 26,921 | | | | | | * | | |
| Bernadette Connaughton(5) | | | | | 8,244 | | | | | | * | | |
| Bruce Eaton(6) | | | | | 270,791 | | | | | | * | | |
| Andrew Hirsch(7) | | | | | 71,228 | | | | | | * | | |
| Jessica Hopfield, Ph.D.(8) | | | | | 80,390 | | | | | | * | | |
| Elliott Levy, M.D. | | | | | — | | | | | | — | | |
| Baisong Mei, M.D., Ph.D. | | | | | — | | | | | | — | | |
| James C. Mullen(9) | | | | | 464,028 | | | | | | * | | |
| Gilmore O’Neill, M.B., M.M.Sc.(10) | | | | | 259,216 | | | | | | * | | |
| Emma Reeve(11) | | | | | 4,579 | | | | | | * | | |
| Michelle Robertson(12) | | | | | 192,125 | | | | | | * | | |
| David T. Scadden, M.D.(13) | | | | | 46,152 | | | | | | * | | |
| Mark S. Shearman, Ph.D.(14) | | | | | 71,699 | | | | | | * | | |
| Akshay K. Vaishnaw, M.D., Ph.D.(15) | | | | | 80,766 | | | | | | * | | |
| All executive officers and directors as a group (13 persons)(16) | | | | | 1,504,440 | | | | | | 2.2% | | |
Name of Beneficial Owner | Shares Beneficially Owned | Percentage of Shares Beneficially Owned | ||||||
5% Stockholders | ||||||||
State Street Corporation(1) | 8,760,151 | 10.7 | % | |||||
The Vanguard Group, Inc.(2) | 8,461,701 | 10.3 | % | |||||
BlackRock Inc.(3) | 7,838,969 | 9.5 | % | |||||
Deep Track Capital, LP(4) | 5,473,086 | 6.7 | % | |||||
Named Executive Officers and Directors | ||||||||
Linda C. Burkly, Ph.D.(5) | 3,100 | * | ||||||
Meeta Chatterjee, Ph.D.(6) | 84,614 | * | ||||||
Bernadette Connaughton(7) | 66,488 | * | ||||||
Bruce Eaton(8) | 309,950 | * | ||||||
Andrew Hirsch(9) | 121,228 | * | ||||||
Jessica Hopfield, Ph.D.(10) | 130,390 | * | ||||||
Elliott Levy, M.D. (11) | 16,667 | * | ||||||
Erick Lucera(12) | 88,808 | * | ||||||
Baisong Mei, M.D., Ph.D. (13) | 134,132 | * | ||||||
Gilmore O’Neill, M.B., M.M.Sc.(14) | 609,675 | * | ||||||
Emma Reeve(15) | 59,158 | * | ||||||
Michelle Robertson(16) | 212,017 | * | ||||||
David T. Scadden, M.D.(17) | 96,152 | * | ||||||
Akshay K. Vaishnaw, M.D., Ph.D.(18) | 130,766 | * | ||||||
All executive officers and directors as a group (12 persons)(19) | 1,541,178 | 1.9 | % |
By the Audit Committee Editas Medicine, Inc. | |||||
Emma Reeve, Chair Meeta Chatterjee, Ph.D. Andrew Hirsch Meeta Chatterjee, Ph.D. Andrew Hirsch Elliott Levy, M.D. |
| | | | 2022 | | | 2021 | | ||||||
| Audit fees(1) | | | | $ | 900,390 | | | | | $ | 896,010 | | |
| Audit-related fees | | | | | — | | | | | | — | | |
| Tax fees(2) | | | | | 20,000 | | | | | | 23,995 | | |
| All other fees | | | | | — | | | | | | — | | |
| Total fees | | | | $ | 920,390 | | | | | $ | 920,005 | | |
2023 | 2022 | |||||||
Audit fees(1) | $ | 954,250 | $ | 900,390 | ||||
Audit-related fees | — | — | ||||||
Tax fees(2) | 25,750 | 20,000 | ||||||
All other fees | — | — | ||||||
Total fees | $ | 980,000 | $ | 920,390 |